Clinical trials for Primary central nervous system lymphoma
71 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 3NCT07104032IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical Co. Ltd · PI: Clinical Team
- RECRUITINGPhase 2NCT07416890Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaZhejiang Cancer Hospital · PI: Haiyan Yang, MD
- RECRUITINGPhase 2NCT07410520PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPhase 2NCT07350850A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)Tongji Hospital
- RECRUITINGPhase 2NCT07062627Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaHyungwoo Cho · PI: Hyungwoo Cho, Ph.D
- RECRUITINGPhase 2NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaJuno Therapeutics, Inc., a Bristol-Myers Squibb Company · PI: Bristol-Myers Squibb
- RECRUITINGPhase 2NCT06931652Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and RituximabThe Lymphoma Academic Research Organisation · PI: Hervé Pr. Ghesquieres, MD
- RECRUITINGPhase 1NCT07082868A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)Memorial Sloan Kettering Cancer Center · PI: Christian Grommes, MD
- RECRUITINGPhase 1NCT06922604Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System LymphomaCity of Hope Medical Center · PI: James Godfrey
- RECRUITINGPhase 1NCT06607549Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)University of Utah · PI: Narendranath Epperla, MD, MS
- RECRUITINGNCT07188077Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGN/ANCT06832267Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCLZhejiang Cancer Hospital · PI: Haiyan Yang
- RECRUITINGN/ANCT07074470Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSLThe First Affiliated Hospital of Soochow University
- RECRUITINGNCT06755619CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)Nordic Lymphoma Group
- RECRUITINGPhase 2NCT06737250NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSLNOBO Medicine · PI: Hong Yul An, Dr
- RECRUITINGPhase 1NCT06475235Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLDana-Farber Cancer Institute · PI: Lakshmi Nayak, MD
- RECRUITINGPHASE1, PHASE2NCT06554561A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT06556199A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- ACTIVE NOT RECRUITINGPhase 1NCT06541665Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSLOno Pharmaceutical Co. Ltd · PI: Project Leader
- RECRUITINGPhase 2NCT05681195Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomasBaptist Health South Florida · PI: Yuliya Linhares, M.D.
- RECRUITINGPhase 2NCT06175000Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial ResponseProvidence Health & Services · PI: Prakash Ambady, MD
- RECRUITINGPhase 2NCT05998642Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaCanadian Cancer Trials Group · PI: Jean-Francois Larouche
- RECRUITINGPhase 2NCT06876688Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell LymphomaRuijin Hospital
- RECRUITINGPHASE1, PHASE2NCT06132737[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma PatientsPentixapharm AG · PI: Bastian von Tresckow, Prof. Dr. med.
- RECRUITINGPhase 2NCT06940791Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)Kyorin University
- RECRUITINGNCT05828628CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers StudyRoyal Marsden NHS Foundation Trust · PI: Ian Chau
- RECRUITINGN/ANCT06445257A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLHuai'an First People's Hospital
- RECRUITINGPhase 2NCT05926427Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRuijin Hospital
- RECRUITINGPhase 3NCT06830421Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL PatientsUniversity Hospital Freiburg
- RECRUITINGPHASE1, PHASE2NCT05698147Selinexor in Combination With MTX+Ritu to Treat R/R CNSLTong Chen, MD · PI: Tong Chen, Ph.D
- RECRUITINGPhase 1NCT05625594Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System LymphomaCity of Hope Medical Center · PI: Tanya Siddiqi
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05485753A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)Sichuan Baili Pharmaceutical Co., Ltd. · PI: Wenbin Li
- RECRUITINGN/ANCT06946407Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System LymphomaFengYan Jin
- RECRUITINGPhase 2NCT05931328The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.The First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEarly Phase 1NCT05651178Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma PatientsHrain Biotechnology Co., Ltd. · PI: Qingming Wang, M.D.
- ACTIVE NOT RECRUITINGNCT05782374Real World Data on Ibrutinib Use in PCNSL Rel/RefIRCCS San Raffaele
- RECRUITINGPhase 2NCT05600660Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGPHASE1, PHASE2NCT05351593Tafasitamab Plus Lenalidomide in Relapsed CNS LymphomaJames Rubenstein · PI: James Rubenstein, MD, PhD
- RECRUITINGPhase 2NCT05549284Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Affiliated Hospital to Academy of Military Medical Sciences
- RECRUITINGPhase 4NCT05518383B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGPhase 2NCT05390749Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLPeking Union Medical College Hospital
- RECRUITINGPhase 2NCT05260619Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System LymphomaSeoul National University Bundang Hospital
- RECRUITINGPhase 2NCT07014943High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System LymphomaSichuan University
- ACTIVE NOT RECRUITINGPhase 2NCT04947319Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Ono Pharmaceutical Co. Ltd · PI: Project Leader
- RECRUITINGPhase 2NCT05209620Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaHenan Cancer Hospital · PI: Zhihua Yao, M.D. Ph.D
- RECRUITINGPhase 1NCT05098613Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL PatientsUniversity of Colorado, Denver · PI: Manali Kamdar, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05036577A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLHuashan Hospital · PI: Tong Chen
- RECRUITINGNCT06263361Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.IRCCS San Raffaele · PI: Pietro Mortini, MD, Prof.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04906902Acalabrutinib in CNSLDana-Farber Cancer Institute · PI: Lakshmi Nayak, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04931368OptiMATe: De-escalated Induction Treatment in Primary CNS LymphomaKlinikum Stuttgart · PI: Gerald Illerhaus, Prof
- RECRUITINGPhase 2NCT04906096Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLLakshmi Nayak, MD · PI: Lakshmi Nayak, MD
- RECRUITINGPhase 2NCT05425654RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLNational Research Center for Hematology, Russia
- RECRUITINGPhase 1NCT04830137A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNurix Therapeutics, Inc. · PI: Study Director
- ACTIVE NOT RECRUITINGPhase 1NCT04462328Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaWashington University School of Medicine · PI: Neha Mehta-Shah, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT04443829Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS LymphomaUniversity College, London · PI: Claire Roddie
- ACTIVE NOT RECRUITINGPhase 1NCT04688151Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.National Health Research Institutes, Taiwan · PI: Shang-Ju Wu, M.D
- RECRUITINGPhase 2NCT04737889Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System LymphomaHenan Cancer Hospital · PI: Zhihua Yao, M.D. Ph.D
- ACTIVE NOT RECRUITINGPhase 1NCT04608487Axi-cel in CNS LymphomaDana-Farber Cancer Institute · PI: Caron Jacobson, MD
- RECRUITINGPhase 2NCT04627753Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.Kim, Seok Jin · PI: Seok Jin Kim, MD, PhD
- RECRUITINGN/ANCT05036564Diagnosis; Objective RespOnse; THErApyIRCCS San Raffaele · PI: Andrés J.M. Ferreri, MD
- ACTIVE NOT RECRUITINGPhase 2NCT04548648A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS LymphomasUNC Lineberger Comprehensive Cancer Center · PI: Christopher Dittus
- RECRUITINGPHASE1, PHASE2NCT04421560Pembrolizumab, Ibrutinib and Rituximab in PCNSLDana-Farber Cancer Institute · PI: Lakshmi Nayak, MD
- RECRUITINGPhase 2NCT04070040Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)Beijing Sanbo Brain Hospital
- RECRUITINGNCT04006561Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated BoostChang Gung Memorial Hospital
- RECRUITINGPHASE1, PHASE2NCT03328078CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)Curis, Inc.
- ACTIVE NOT RECRUITINGNCT03962127MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central NorwayNorwegian University of Science and Technology · PI: Bent Indredavik, PhD Prof
- ACTIVE NOT RECRUITINGPhase 1NCT02203526Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS LymphomaNational Cancer Institute (NCI) · PI: Rahul Lakhotia, M.D.
- RECRUITINGNCT05114330Secondary Central Nervous System Lymphoma Registry - CharitéCharite University, Berlin, Germany
- RECRUITINGPHASE2, PHASE3NCT02836158Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSLNavy General Hospital, Beijing · PI: Liren Qian, M.D.
- RECRUITINGPHASE2, PHASE3NCT02657785Treatment of PCNSL With R-IDARAM and Intrathecal ImmunochemotherapyNavy General Hospital, Beijing · PI: Liren Qian, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT00863460Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young PatientsInstitut Curie · PI: Carole Soussain, MD